Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration.
about
Anti-vascular endothelial growth factor for neovascular age-related macular degenerationOcular diseases: immunological and molecular mechanismsManagement of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in developmentCurrent perspectives on ranibizumabHealth State Utility Values for Age-Related Macular Degeneration: Review and Advice.Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.Switching to less expensive blindness drug could save medicare part B $18 billion over a ten-year periodGuidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).Ziv-aflibercept in macular disease.Intravitreal Bevacizumab Versus Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration: Findings from a Cochrane Systematic ReviewCost-Effectiveness Models in Age-Related Macular Degeneration: Issues and Challenges.Treatment of systemic hypertension is important for improvement of macular edema associated with retinal vein occlusion.Intravitreal injection of ziv-aflibercept in the treatment of choroidal and retinal vascular diseases.The Effect of CM082, an Oral Tyrosine Kinase Inhibitor, on Experimental Choroidal Neovascularization in Rats.A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1.Three-month outcome of ziv-aflibercept for exudative age-related macular degeneration.The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective.
P2860
Q24194251-14FEEF56-D1C5-4ECE-930C-A6642404E5AFQ26747534-310FF7C0-D6BC-436C-A6F2-13BAA9ACFC7EQ26824335-2AB0E3CF-DE16-4CC8-8086-DDF6D38BE921Q28082383-B493D7F7-49A5-4974-9421-44D7B8573A9FQ30393038-1C7E3B14-8108-4B03-BA8B-091FA30BB25BQ33995880-E41011CF-5338-4E82-BC6F-091E328822C0Q34062494-65C6CDF2-55B9-42F6-97AE-3A3C7020A6CDQ34092454-ED735B79-1C28-413B-8140-EF67BD79A040Q35899591-13D8E4D0-04A4-4A67-8ED1-17AF38B663D9Q36414769-9E7F3C32-8586-4451-8817-93581F0A5D57Q38631993-043E4849-76AB-4945-BF3B-02BF45372320Q40022718-674F37EE-1231-4897-B952-C60F87E3B7A4Q40039608-1B13D7F1-C844-4B19-9B40-C8E442878B33Q47136171-7E3E9168-2F27-4790-97FC-2FE6A9A5DFCBQ51013749-BB5470A2-93E7-4D42-BFE0-1B4EBFC4B993Q53134473-0BE88C2A-9496-4FC4-B594-A5AAFF61BD03Q54969941-BA30F2FF-D8AD-4CF2-8A87-ABEF85FB0E98
P2860
Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Cost-effectiveness of bevacizu ...... vascular macular degeneration.
@ast
Cost-effectiveness of bevacizu ...... vascular macular degeneration.
@en
type
label
Cost-effectiveness of bevacizu ...... vascular macular degeneration.
@ast
Cost-effectiveness of bevacizu ...... vascular macular degeneration.
@en
prefLabel
Cost-effectiveness of bevacizu ...... vascular macular degeneration.
@ast
Cost-effectiveness of bevacizu ...... vascular macular degeneration.
@en
P2093
P2860
P1433
P1476
Cost-effectiveness of bevacizu ...... ovascular macular degeneration
@en
P2093
David W Hutton
Paul P Lee
Tavag Mrinalini
P2860
P304
P356
10.1016/J.OPHTHA.2013.10.037
P577
2014-01-07T00:00:00Z